Will Garvin, shareholder in the firm's Life Sciences section, presented a webinar, "Introduction to the Regulation of Cannabis-Derived Products," hosted by the Food & Drug Law Institute, on August 1.
Approaches to the emerging business of cannabis products seem to change on a daily basis: Legal? Illegal? Beneficial? Harmful? This webinar provided an overview of the current state of cannabis regulation. The panel discussed scientific definitions of various cannabis-derived substances, including CBD, THC and hemp, and the pharmacology of how these substances can affect the body. The group then provided updates to various federal agencies’ regulation of cannabis products, as well as implications for companies operating in states that have legalized cannabis for medical and/or recreational purposes. They also provided an update on international governing bodies’ approaches to cannabis regulation.